The Max Delbrück Center for Molecular Medicine in the Helmholtz Association aims to transform tomorrow’s medicine through our discoveries of today. At locations in Berlin-Buch, Berlin-Mitte, Heidelberg and Mannheim, our researchers harness interdisciplinary collaboration to decipher the complexities of disease at the systems level – from molecules and cells to organs and the entire organism. Through academic, clinical, and industry partnerships, as well as global networks, we strive to translate biological discoveries into applications that enable the early detection of deviations from health, personalize treatment, and ultimately prevent disease. First founded in 1992, the Max Delbrück Center today inspires and nurtures a diverse talent pool of 1,800 people from over 70 countries. We are 90 percent funded by the German federal government and 10 percent by the state of Berlin.
Disease Area
Biomedical Research, Medicine, Human Health
Senior business development manager
Max Delbrück Center for Molecular Medicine
Innovation Market Specialist
Max Delbrück Center for Molecular Medicine
Innovation and Entrepreneurship Manager
Max Delbrück Center for Molecular Medicine
Technologie-Managerin
Max Delbrück Center for Molecular Medicine
Head of Innovation & Entrepreneurship
Max Delbrück Center for Molecular Medicine
Scientist at the Max-Delbrück-Center
Max Delbrück Center for Molecular Medicine
Innovation Manager
Max Delbrück Center for Molecular Medicine
Postdoc | Founder-to-be
Max Delbrück Center for Molecular Medicine
Max Delbrück Center for Molecular Medicine
PhD Researcher
Max Delbrück Center for Molecular Medicine
PhD student
Max Delbrück Center for Molecular Medicine
PostDoc / CO-Founder of CARTemis Therapeutics
Max Delbrück Center for Molecular Medicine
head of genomics cf
Max Delbrück Center for Molecular Medicine
Doctoral Researcher
Max Delbrück Center for Molecular Medicine
Scientific Director BIMSB
Max Delbrück Center for Molecular Medicine
Max Delbrück Center for Molecular Medicine
Max Delbrück Center for Molecular Medicine
Prof./Group Leader
Max Delbrück Center for Molecular Medicine
Max Delbrück Center for Molecular Medicine
Group Leader
Max Delbrück Center for Molecular Medicine
Team Leader NGS
Max Delbrück Center for Molecular Medicine
PhD researcher
Max Delbrück Center for Molecular Medicine
PhD student
Max Delbrück Center for Molecular Medicine
Max Delbrück Center for Molecular Medicine
PostDoc; Immune-monitoring/Biomarkers
Max Delbrück Center for Molecular Medicine
Postdoctoral Researcher
Max Delbrück Center for Molecular Medicine
Project Management
Max Delbrück Center for Molecular Medicine
Staff scientist
Max Delbrück Center for Molecular Medicine
PostDoc / Bioinformatics Researcher
Max Delbrück Center for Molecular Medicine
Postdoctoral Scientist Technology Development
Max Delbrück Center for Molecular Medicine
Management Scientific Infrastructure
Max Delbrück Center for Molecular Medicine
PI
Max Delbrück Center for Molecular Medicine
Research associate
Max Delbrück Center for Molecular Medicine
PhD student
Max Delbrück Center for Molecular Medicine
Project Manager
Max Delbrück Center for Molecular Medicine
Partnership
Selective Inhibitors of Genotoxic Stress Induced NFκB Pathway for Cancer Therapy
Selective Inhibitors for cancer therapy for the treatment of therapeutic resistance in chemotherapy and irradiation therapy
Technologie-Managerin at Max Delbrück Center for Molecular Medicine
Berlin, Germany
Investment
Selective Inhibitors of Genotoxic Stress Induced NFκB Pathway for Cancer Therapy
Selective Inhibitors for cancer therapy for the treatment of therapeutic resistance in chemotherapy and irradiation therapy
Technologie-Managerin at Max Delbrück Center for Molecular Medicine
Berlin, Germany
Partnership
Small molecules inhibiting SARS-coronavirus infections
We develop an inexpensive, preventive, oral or inhalative drug for COVID-19 and other coronavirus infections.
Group Leader at Max Delbrück Center for Molecular Medicine
Berlin, Germany